Navigation Links
Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company
Date:4/30/2008

BATESVILLE, Ind., April 30 /PRNewswire-FirstCall/ -- Hillenbrand, Inc. (NYSE: HI) today announced that its Board of Directors declared the company's first dividend as a publicly traded company of $0.1825 per share on the company's common stock. The dividend is payable June 30, 2008 to shareholders of record at the close of business on June 16, 2008.

"The decision by our board to approve this inaugural dividend is based on the strength of our fundamentals, including strong and consistent cashflows, and demonstrates our long-term commitment to creating and increasing shareholder value," said Hillenbrand's President and CEO, Kenneth A. Camp.

ABOUT HILLENBRAND, INC.

Hillenbrand, Inc. is the holding company for Batesville Casket Company, a leader in the North American death care industry through the sale of funeral services products, including burial caskets, cremation caskets, containers and urns, selection room display fixturing and other personalization and memorialization products.

Batesville Casket Company ... helping families honor the lives of those they love.

http://www.hillenbrandinc.com

Certain statements in this release contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the future plans, objectives, beliefs, expectations, representations, and projections of Hillenbrand, Inc. (the "Company"). The Company has tried, wherever possible, to identify these forward looking statements using words such as "intend," "anticipate," "believe," "plan," "expect," "may," "goal," "become," "pursue," "estimate," "strategy," "will," "projection," "forecast," "continue," "accelerate," "promise," "increase," "higher," "lower," "reduce," "improve," "expand," "progress," "potential" or the negative of those terms, other variations of them, or by comparable terminology. The absence of such terms, however, does not mean that the statement is not forward looking. It is important to note that forward looking statements are not guarantees of future performance, and the Company's actual results could differ materially from those set forth in any forward looking statements. Factors that could cause actual results to differ from forward looking statements include, but are not limited to: the antitrust litigation in which the Company is currently a defendant; the Company's dependence on its relationships with several large national providers; continued fluctuations in mortality rates and increased cremations; ongoing involvement in claims, lawsuits, and governmental proceedings; failure of the Company's announced strategic initiatives to achieve expected growth, efficiencies, or cost reductions; disruptions in the Company's business or other adverse consequences resulting from the spin-off of the Company from Hillenbrand Industries, Inc.; competition from nontraditional sources in the funeral service business; increased costs or unavailability of raw materials; labor disruptions; the ability to retain executive officers and other key personnel; and certain tax-related matters. For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward looking statements, see the discussions under the heading "Risk Factors" in the Information Statement dated March 17, 2008 filed as Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2008. The Company assumes no obligation to update or revise any forward looking statements.


'/>"/>
SOURCE Hillenbrand, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Torchmark Corporation Declares Dividend
3. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
4. STERIS Corporation Declares Regular Quarterly Dividend
5. State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week
6. Lilly Declares Second-Quarter Dividend
7. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
8. NCPA Declares April 14 - 18 Protect Your Pharmacy Week
9. P&G Declares a 14% Dividend Increase
10. Coalition to Prevent Deep-Vein Thrombosis (DVT) Turns Awareness Into Action as it Declares First-Of-Its-Kind National DVT Screening Day
11. Birner Dental Management Services, Inc. Declares $.17 Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: